Reviews in Pharmaceutical Sciences

Objective: The article seeks to investigate research conducted on hemovigilance using a bibliometric analysis. Quantitative methods examine trends in publication, high profile magazines, frequently cited documents, notable countries and organizations, ownership patterns, and collaboration among authors in this field. Methods: The Scopus database was used to gather data for the study on document categories, extensively cited publications, highly regarded journals, contributions by nation, and other pertinent details. The VOS viewer programme was used for data analysis and representation. Result: A bibliometric study covering scientific contributions related to hemovigilance revealed a total of 962 publications across 882 journals and books. The works authored by skilled researchers in prestigious journals underscored the primary research areas within this field. With 95 documents, the United States has become the country that contributes the most to scientific production. Conclusion: As such, the results of this research may provide a basis upon which specialists might develop a hemovigilance road map. Research design may be developed to gather comprehensive data on patients' blood types, storage methods, transfusion protocols, and all aspects involved in maintaining the lifecycle of blood. Research collaboration is encouraged as it makes it easier to publish integrated techniques and data. Increasing the scope of our knowledge will enable us to respond more effectively to complex issues that might impact people all around the world.

Plant-derived bioactive compounds exhibit significant therapeutic potential, including antioxidant, anti-inflammatory, antimicrobial, and anticancer activities. However, their clinical application is often limited by poor solubility, low bioavailability, rapid metabolism, and instability. Nanotechnology-based delivery systems such as nanoparticles, liposomes, niosomes, and nanoemulsions offer effective solutions by enhancing stability, bioavailability, controlled release, and targeted delivery. This editorial highlights the role of nanoformulations in overcoming pharmacokinetic limitations and advancing the therapeutic efficacy of phytochemicals.

Lysozyme is a naturally occurring antimicrobial enzyme present in various biological secretions. It exhibits bacteriolytic, antiviral, antibiofilm, and immunomodulatory properties. This editorial article highlights its mechanisms and explores its biomedical potential in the context of antimicrobial resistance [1,2].

Stimuli-responsive nanocarriers represent an advanced and intelligent approach in modern drug delivery systems designed to achieve site-specific and controlled drug release. These nanocarriers are engineered to respond to specific internal or external stimuli such as pH, enzymes, redox potential, temperature, light, magnetic fields, and ultrasound. Upon exposure to these stimuli, structural or chemical changes occur in the nanocarriers, triggering the release of the encapsulated drug at the targeted site. This smart delivery strategy enhances therapeutic efficacy while minimizing systemic toxicity and side effects associated with conventional drug delivery methods. Stimuli responsive nanocarriers have gained significant attention in the treatment of diseases such as cancer, infections, and neurological disorders due to their ability to improve drug stability, bioavailability, and targeting efficiency. Furthermore, advancements in nanotechnology and biomaterials have facilitated the development of multifunctional and multi-stimuli responsive systems. Overall, these smart nanocarriers offer promising potential for future personalized medicine and targeted therapeutic applications.

Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the leading cause of dementia worldwide. Increasing evidence suggests a significant association between Alzheimer’s disease and epileptic activity. Although seizures were historically considered a rare complication of Alzheimer’s disease, recent studies indicate that both clinical seizures and subclinical epileptiform activity occur more frequently in patients with AD than previously recognized. Neurodegenerative processes associated with Alzheimer’s disease, including amyloid-β accumulation, tau pathology, synaptic dysfunction, and neuronal network disruption, may increase neuronal hyperexcitability and contribute to seizure susceptibility. Several epidemiological and clinical studies have reported that individuals with Alzheimer’s disease have a significantly higher risk of developing epilepsy compared with age-matched individuals without dementia. Furthermore, epileptiform activity has been associated with accelerated cognitive decline and disease progression. This narrative review examines current scientific literature regarding the prevalence, underlying mechanisms, and clinical implications of epilepsy in patients with Alzheimer’s disease. Understanding the relationship between these two neurological conditions is important for improving early detection, clinical management, and long-term outcomes for affected patients.